IBS-D Drug Launched as Two-Week Treatment Pack
Salix announced the availability of Xifaxan 550 in a new two-week treatment Pack. The Xifaxan two-week Pack contains 42 tablets, providing a full course of treatment for irritable bowel syndrome with diarrhea (IBS-D).
Xifaxan 550, a rifamycin antibiotic, is also indicated for the reduction in risk of overt hepatic encephalopathy occurrence. Rifaximin is a semi-synthetic derivative of rifampin and acts by binding to the beta subunit of bacterial DNA-dependent RNA polymerase blocking one of the steps in transcription. This results in inhibition of bacterial protein synthesis and consequently inhibits the growth of bacteria.
Xifaxan 550 is already supplied in 60-count bottles and cartons.
For more information call (800) 508-0024 or visit Xifaxan.com.